{
    "clinical_study": {
        "@rank": "40453", 
        "brief_summary": {
            "textblock": "RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells\n      and slow the growth of colorectal cancer.\n\n      PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have\n      locally advanced or metastatic colorectal cancer that has not responded to chemotherapy."
        }, 
        "brief_title": "ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "September 2003", 
            "@type": "Actual"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the progression-free rate at 16 weeks, response rate, time to treatment\n           failure, and survival of patients treated with gefitinib for locally advanced or\n           metastatic colorectal adenocarcinoma that is refractory to fluorouracil, irinotecan,\n           and capecitabine.\n\n        -  Correlate the pharmacodynamic effects of this drug with indices of clinical benefit\n           (e.g., tumor growth inhibition, time to tumor progression, and survival) in these\n           patients.\n\n        -  Determine whether the status of epidermal growth factor receptor activation and\n           signaling are predictive of clinical outcome in patients treated with this drug.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive oral gefitinib once daily. Treatment continues every 28 days in the absence\n      of disease progression or unacceptable toxicity.\n\n      PROJECTED ACCRUAL: A total of 18-46 patients will be accrued for this study within 5-12\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically or cytologically confirmed colorectal adenocarcinoma\n\n               -  Metastatic or locally advanced disease\n\n               -  Not amenable to curative therapy\n\n          -  Documentation of disease progression within the past 6 months\n\n          -  Previously treated with fluoropyrimidine- and irinotecan-based chemotherapy\n             (including capecitabine) administered either concurrently (no more than 2 regimens)\n             or sequentially (no more than 3 regimens) for advanced disease\n\n          -  At least 1 unidimensionally measurable lesion\n\n               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan\n\n          -  No known brain metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-2 OR\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  More than 12 weeks\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n\n          -  AST/ALT no greater than 3 times ULN (5 times ULN if liver metastasis present)\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 times ULN OR\n\n          -  Creatinine clearance at least 60 mL/min\n\n        Cardiovascular:\n\n          -  No symptomatic congestive heart failure\n\n          -  No unstable angina pectoris\n\n          -  No cardiac arrhythmia\n\n        Ophthalmic:\n\n          -  No significant ophthalmic conditions, including:\n\n               -  Severe dry-eye syndrome\n\n               -  Keratoconjunctivitis sicca\n\n               -  Sjogren's syndrome\n\n               -  Severe-exposure keratopathy\n\n               -  Disorders that may increase the risk for epithelium-related complications (e.g.,\n                  bullous keratopathy, aniridia, severe chemical burns, or neutrophilic keratitis)\n\n        Other:\n\n          -  Able to take oral gefitinib\n\n          -  No other uncontrolled concurrent illness\n\n          -  No ongoing or active infection\n\n          -  No psychiatric illness or social situation that would preclude study participation\n\n          -  No prior gastrointestinal disorders (e.g., malabsorption syndrome)\n\n          -  No prior allergic reactions attributed to compounds of similar chemical or biological\n             composition to gefitinib\n\n          -  No other prior malignancy except carcinoma in situ of the cervix, nonmelanoma skin\n             cancer, or other cancer from which the patient has been free of evident disease for\n             more than 5 years and/or has less than a 20-30% estimated likelihood of recurrence\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 30 days since prior chemotherapy and recovered\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  Not specified\n\n        Surgery:\n\n          -  No prior gastric resection\n\n        Other:\n\n          -  No other prior therapy for advanced disease\n\n          -  No concurrent combination antiretroviral therapy for HIV-positive patients\n\n          -  No other concurrent investigational or commercial agents or therapies for the\n             malignancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "February 14, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00030524", 
            "org_study_id": "CDR0000069174", 
            "secondary_id": [
                "UTHSC-0015011185", 
                "SACI-IDD-01-01", 
                "NCI-3753"
            ]
        }, 
        "intervention": {
            "intervention_name": "gefitinib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Gefitinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "stage III colon cancer", 
            "stage IV colon cancer", 
            "stage III rectal cancer", 
            "stage IV rectal cancer", 
            "recurrent colon cancer", 
            "recurrent rectal cancer", 
            "adenocarcinoma of the colon", 
            "adenocarcinoma of the rectum"
        ], 
        "lastchanged_date": "October 26, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/UTHSC-0015011185"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Institute for Drug Development"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78284-7811"
                    }, 
                    "name": "University of Texas Health Science Center at San Antonio"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Clinical, Biological and Pharmacological Study of ZD1839 in Patients With Advanced Colorectal Carcinoma Refractory to 5-Fluorouracil (5-FU) and Irinotecan Chemotherapy", 
        "overall_official": {
            "affiliation": "The University of Texas Health Science Center at San Antonio", 
            "last_name": "Chris H. Takimoto, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2003", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00030524"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "The University of Texas Health Science Center at San Antonio", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "The University of Texas Health Science Center at San Antonio", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2002", 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }, 
    "geocoordinates": {
        "Institute for Drug Development": "29.424 -98.494", 
        "University of Texas Health Science Center at San Antonio": "29.424 -98.494"
    }
}